Skip to main content

Table 1 Eligibility criteria

From: Rectal indomethacin alone versus indomethacin and prophylactic pancreatic stent placement for preventing pancreatitis after ERCP: study protocol for a randomized controlled trial

Any patient undergoing endoscopic retrograde cholangiopancreatography (ERCP) in whom pancreatic stent placement is planned for post-ERCP pancreatitis prevention, is at least 18 years old, provides informed consent, and:
Has one of the following criteria: Or two of the following criteria:
 Clinical suspicion of sphincter of Oddi dysfunction Age under 50 years old and of female gender
 History of post-ERCP pancreatitis History of recurrent pancreatitis
 Pancreatic sphincterotomy At least 3 pancreatic injections, with at least 1 injection to tail
 Pre-cut (access) sphincterotomy Pancreatic acinarization
 Difficult cannulation Pancreatic brush cytology
 Short duration (≤1 min) balloon dilation of intact biliary sphincter  
Exclusion criteria
 Ampullectomy
 Case in which a pancreatic stent is placed for therapeutic intent
 Unwillingness or inability to consent for the study
 Pregnancy
 Breastfeeding mother
 Standard contraindications to ERCP
 Allergy to aspirin or NSAIDs
 Known renal failure (creatinine >1.4 mg/dl)
 Ongoing or recent (within 2 weeks) hospitalization for gastrointestinal hemorrhage
 Ongoing or recent (within 1 week) hospitalization for acute pancreatitis
 Known chronic calcific pancreatitis
 Pancreatic head mass
 Procedure performed on major papilla/ventral pancreatic duct in patient with pancreas divisum (no manipulation of minor papilla)
 ERCP for biliary stent removal or exchange without anticipated pancreatogram
 Subjects with prior biliary sphincterotomy now scheduled for repeat biliary therapy without anticipated pancreatogram
 Anticipated inability to follow protocol
 Absence of rectum
  1. NSAIDs non-steroidal anti-inflammatory drugs